Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple Myeloma

NCT05789303 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT05789303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05789303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple Myeloma
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Recruiting
Start date
May 30, 2023
Completion date
July 1, 2028
Enrollment
83 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, relapse multiple myeloma